SDC1 and plasma cell myeloma: Paired samples before the last treatment and at relapse were analyzed after sorting each sample into a CD138+ plasma/myeloma cell fraction and a CD138– BME fraction that were processed independently for scRNA-seq analysis (Fig. 1a, b).